Polyrizon (PLRZ) news
Recent news
Polyrizon Ltd.: Polyrizon files for U.S. patent application to expand IP moat around intranasal drug-delivery platform
Polyrizon Ltd. (Nasdaq: PLRZ) has taken a step to strengthen its intellectual property (IP) position by publishing U.S. patent application No. US 2024/0358741 A1, titled “Mucoadhesive Polymers for Nasal Drug Delivery” . The application outlines the company’s Trap & Target™ (T&T) mucoadhesive…
AInvest Wire · 7d agoPolyrizon enrolls first patient in U.S. clinical study of Nasarix (PL-14) allergy blocker
AInvest Wire · Sep 22, 2026Polyrizon Ltd.: Polyrizon: Closing of $4.0M registered direct offering, placement
Polyrizon Ltd. (OTCQB: PYZN) announced the successful closing of a $4.0 million registered direct offering and placement on August 31, 2026. The company issued 10,000,000 shares of common stock at a price of $0.40 per share to accredited investors. The offering was conducted under the company’s…
AInvest Wire · Sep 4, 2026Polyrizon reports $4M registered direct offering and placement
AInvest Wire · Sep 3, 2026Polyrizon: Co & Arrow Aviation entered into letter agreement extending exclusivity period & initial negotiation period under MOU to June 30
Polyrizon Ltd. (Nasdaq: PLRZ) and Arrow Aviation Ltd. have entered into a letter agreement to extend the exclusivity period and initial negotiation period under their previously announced Memorandum of Understanding (MOU) to June 30, 2026. The MOU, initially signed on February 4, 2026, outlines…
AInvest Wire · Jun 5, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.